Wisevoter
Philadelphia

Cerenome Presents New REYOBIQ Data in Philadelphia

New research details how the targeted radiotherapy candidate alters the tumor microenvironment to improve immune response.

Updated on Oct. 21, 2026 in Cancer

Isometric editorial illustration of a precision radiation therapy instrument, representing medical research into localized tumor treatment.
Cerenome presented preclinical data on its targeted radiotherapy candidate, REYOBIQ, during the Rivkin Ovarian Cancer Research Symposium in Philadelphia this week. AI Illustration. Upload story photo >

Live Poll

Should pharmaceutical companies focus more on developing new therapies or enhancing existing treatment options?

Cerenome shared preclinical data at the Rivkin Ovarian Cancer Research Symposium in Philadelphia, highlighting the immunomodulatory effects of its therapy, REYOBIQ. The study demonstrates improved antitumor activity when the treatment is combined with anti-PD-1 checkpoint blockade in mouse models.

Why it matters

Epithelial ovarian cancer typically resists checkpoint inhibitor monotherapy because of immune-suppressive tumor microenvironments. This research suggests a potential pathway to overcome that resistance through localized radiation delivery.

Researchers observed that REYOBIQ treatments ranging from 0.075 to 1.257 mCi improved survival in a dose-dependent manner. Combination therapy with anti-PD-1 successfully reduced tumor burden and reached a median survival of 65 days.

The players

Cerenome

Cerenome is a biotechnology firm focused on developing targeted radiopharmaceutical therapies for various cancer types.

Rivkin Ovarian Cancer Research Symposium

The Rivkin Ovarian Cancer Research Symposium is a gathering of scientists and medical professionals focused on advancements in ovarian cancer treatment.

The details

REYOBIQ functions by delivering high-dose beta radiation to tumors or fluid compartments, which triggers interferon signaling and antigen presentation within 24 hours. By Day 28, the treatment has been shown to decrease macrophage-associated immunosuppressive programs and increase the presence of cytotoxic T cells.

Timeline

  1. The Rivkin Ovarian Cancer Research Symposium took place in Philadelphia from October 16-18, 2026.

  2. DNA-damage and p53 programs were activated within 24 hours of treatment.

  3. Interferon signaling programs showed measurable increases by Day 28.

The Big Picture

This discovery shifts the trajectory of research into anti-PD-1 checkpoint blockade therapies by providing a mechanism to prime the tumor microenvironment for better immune engagement. It suggests a potential paradigm shift toward combination treatments that physically alter the tumor environment to make it more receptive to existing immunotherapies.

While this study is currently limited to preclinical mouse models, it suggests a future path where targeted radiation could make standard immunotherapies more effective for ovarian cancer patients. Patients should note that human clinical outcomes are not yet established and this treatment is not currently available for therapeutic use.

The takeaway

Preclinical data indicates that combining targeted radiation with checkpoint inhibitors can help overcome immune suppression in ovarian cancer. Future development will focus on assessing if these immunomodulatory benefits translate to broader tumor types and human patients.

Further reading

Find more information on emerging treatments at the Philadelphia Cancer section.

More information

View further company details on the Cerenome corporate website.

Live Poll

Should pharmaceutical companies focus more on developing new therapies or enhancing existing treatment options?